← Leaderboards
Daniel P. Cahill
Massachusetts General Hospital
$3,140,317
Attributed
$5,988,630
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,988,630 · 5
By mechanism
R01$5,217,777 · 3
R21$478,849 · 1
P50$292,004 · 1
Top collaborators
- Hiroaki Wakimoto7 shared
- Mario Luca Suva3 shared
- Priscilla Kaliopi Brastianos2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Bakhos A. Tannous$11,831,527
- Xandra Owens Breakefield$30,735,276
- Christian Elias Badr$3,737,491
- Khalid A Shah$15,720,802
- Vijaya Ramesh$9,458,883
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantMalignant NeoplasmsMissionPublic HealthTumorGeneticMutationGenesMolecularMediatingCellsDna Sequence AlterationIn VivoIsocitrate DehydrogenaseGliomaMetabolismCancer CellTherapeutic TargetYoung AdultDiffuseGene MutationResponsePhenotypeNatural History
Grant awards (13)
Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors$687,277
R01 · FY2025 · CA
Analyzing DNA replication and damage vulnerability in IDH mutant glioma$401,140
R01 · FY2025 · CA · contact PI
Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors$652,794
R01 · FY2024 · CA
Analyzing DNA replication and damage vulnerability in IDH mutant glioma$396,982
R01 · FY2024 · CA · contact PI
Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors$685,752
R01 · FY2023 · CA
Project 2 - Targeting IDH-mutant gliomas (Cahill/Kaelin)$292,004
P50 · FY2023 · CA · contact PI
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$470,540
R01 · FY2022 · CA · contact PI
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$480,143
R01 · FY2021 · CA · contact PI
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$480,143
R01 · FY2020 · CA · contact PI
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$465,738
R01 · FY2019 · CA · contact PI
Targeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomas$497,268
R01 · FY2018 · CA · contact PI
Impact of genetic alterations in meningioma on natural history and therapeutic response$215,484
R21 · FY2017 · NS · contact PI
Impact of genetic alterations in meningioma on natural history and therapeutic response$263,365
R21 · FY2016 · NS · contact PI